A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients

Inclusion Criteria: * Male or female patients age 18-75 year-old; * ECOG 0 - 2; * Newly diagnosed or previously treated Ph+ CML patients in accelerated or blastic Phase; * Adequate organ function; * Written informed consent prior to any study procedures being performed. Exclusion Criteria: * Patients in Chronic and Blastic Phases; * Previously treated with Flumatinib; * Previously documented T315I mutations; * Previous therapy within protocol defined timeframe, including: * hydroxyurea within 24 hr, * Imatinib or Nilotinib or Dasatinib within 28 days) * Cardiac dysfunction ; * History of congenital or acquired bleeding disorders unrelated to CML; * Central nervous system leukemia; * Previous malignancy except CML; * Acute or chronic liver or severe kidney disease unrelated to CML; * Pregnant, breastfeeding, child bearing potential but failed to take effective contraception.